Clinical management of pulmonary aspergillosis

Japan Medical Association Journal

Volumn 48, Issue 12, 2005, Pages 601-606

  Ando, Tsunehiro ^a,b   Shibuya, Kazutoshi ^b  

^a JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^b TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Amphotericin B; Combination therapy; Guidelines; Immunocompromised host; Pulmonary aspergillosis; Voriconazole

Indexed keywords

AMPHOTERICIN B; FLUCYTOSINE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MICAFUNGIN; STEROID; VORICONAZOLE;

ALGORITHM; ASPERGILLOSIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; JAPAN; LUNG ASPERGILLOSIS; OPPORTUNISTIC INFECTION; PATIENT CARE; PRACTICE GUIDELINE; PUBLICATION; REVIEW; SIDE EFFECT; STANDARDIZATION; THORAX RADIOGRAPHY;

EID: 33644507442     PISSN: 13468650     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Yamazaki T, Kume H, Murase S, et al. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol. 1999 Jun;37(6):1732-1738.
2. Binder RE, Faling LJ, Pugatch RD, et al. Chronic necrotizing pulmonary aspergillosis: A discrete clinical entire. Medicine. 1982;61:109-124.
3. Guidelines for the Diagnosis and Management of Deep Seated Mycosis Preparation Committee ad. Shinzaisei Shinkinsyo no Shindan Chiryo Guideline. Tokyo: Ishiyaku Pub., Inc.; 2003. (in Japanese)
4. Kwon-Chung KJ, Bennett JE. Medical Mycology. Philadelphia: Lea & Febiger; 1992.
5. Gefter WB, Weingrad TR, Epstein DM, et al. "Semi-invasive" pulmonary aspergillosis. Radiology. 1981;140:313-321.
6. Denning D, Riniotis K, Dobrashian R, et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: Case series, proposed nomenclature change, and review. Clinical Infectious Disease. 2003;37(suppl 3):S265-280.
7. Bodey GP, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol. 1992;11:99-109.
8. Schafner A, Douglas H, Braude A, et al. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. J Clin Invest. 1982;69:617.
9. Shibuya K, Ando T. Clinicopathological correlates of invasive fungal infections. Abstract, Focus on Fugal Infection. 2003;13: 17-19.
10. Kuhlman JE, Fichman EK, Burch PA, et al. Invasive pulmonary aspergillosis in acute leukemia; characteristic findings on CT, CT-halo sign, and the role of CT in early diagnosis. Radiology. 1985;157:611-614.
11. Abramson S. The air crescent sign. Radiology. 2001;218:230-232.
12. Logan PM, Primack SL, Miller RR, et al. Invasive aspergillosis of the airways; radiographic, CT, and pathologic findings. Radiology. 1994;193:383-388.
13. Verweji PE, Stynen D, Rijs AJMM, et al. Sandwich enzyme-linked immunosorbent assay compared with Pastorex latex agglutination test for diagnosing invasive aspergillosis in immunocompromised patients. J Clin Microbiol. 1995;33:1912-1914.
14. Obayashi T, et al. Determination of plasma(1→3)-β-D-glucan: a new diagnostic aid to deep mycosis. J Med Veter Mycol. 1992;30:275-280.
15. Kami M, Fukui T, Ogawa S, et al. Real-time polymerase chain reaction using blood samples for diagnosis of invasive aspergillosis. Cli Infect Dis. 2001;33:1504-1512.
16. Bardana EJ. Pulmonary aspergillosis. In: Al-Doory Y, Wangner GE, ed. Aspergillosis. Springfield: Thomas; 1985:43-78.
17. McAdams HP, Rosado-de-Christenson ML, Templeton PA, et al. Thoracic mycoses from opportunistic fungi: radiologic-pathologic correlation. Radiographics. 1995;15:271-286.
18. Davies SF, Sarosi GA. Fungal infections. In: Murray JF, Nadel JA. ed. Textbook of Respiratory Medicine, 2nd ed. Philadelphia: WB Saunders; 1994:1161-1200.
19. Palmer LB, Greengerg HE, Schiff MJ. Corticosteroid treatment as a risk factor for invasige aspergillosis in patients with lung disease. Thorax. 1991;46:15-20.
20. Yousem SA. The histological spectrum of chronic necrotizing forms of pulmonary aspergillosis. Hum Pathol. 1997;28:650-656.
21. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764-771.
22. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-415.
23. Kohno S, Masaoka T, Yamaguchi H, et al. A multicenter, open-label clinical study of micafungin (FK463) in the treatment of deep-seated mycosis in Japan. Scand J Infect Dis. 2004;36(5): 372-379.
24. Mukherjee PK, Sheehan DJ, Hitchcock CA, et al. Combination treatment of invasive fungal infections. Clin Mycrobiol Rev. 2005;18(1):163-194.
25. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Des. 2004;39(6): 797-802.
26. Ando T, Ohta K, Morimoto T, et al. Fifteen cases of chronic necrotizing pulmonary aspergillosis. Focus on Fungal Infections 2005;15: abstr 27.